Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.33 |
| ▸ | F2 | P00734 | 4/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | STAT5B | P51692 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20533930 | 0.83 | SMN1; SMN2 (0.39) | NR1H2NR1H3 | |
| SCHEMBL20533917 | 0.76 | APOBEC3A (0.39) | — | |
| SCHEMBL16946634 | 0.74 | GRM2 (0.36) | MCL1 | |
| SCHEMBL21189604 | 0.74 | PDK1 (0.35) | F2MCL1HTR2CSLC6A4 | |
| SCHEMBL30391724 | 0.73 | PDK1 (0.35) | F2MCL1 | |
| SCHEMBL21189605 | 0.73 | PDK1 (0.35) | F2MCL1 | |
| SCHEMBL20533923 | 0.72 | PI4KB (0.54) | PI4KB | |
| SCHEMBL20533931 | 0.72 | RORC (0.37) | — | |
| SCHEMBL21189738 | 0.72 | PDK1 (0.34) | MCL1 | |
| SCHEMBL30392009 | 0.72 | PDK1 (0.34) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PI4K2B, PI4KB | PI4KB 3/4885F2 3024/4885SLC16A3 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.